MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics, Inc. (CMPX)

|||

Cash Flow Overview

Free Cash flow
-$14,914K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from sale or maturities...
    • Share-based compensation
    • Accrued expenses
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Net loss
    • Amortization of premium and disc...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-25,154
-18,317
-15,716
-14,259
Depreciation and amortization
21
15
17
19
Share-based compensation
4,822
5,073
1,825
1,238
Amortization of premium and discount on marketable securities
-198
-206
-1,196
-375
Rou asset amortization
355
353
353
352
Prepaid expenses and other current assets
11
87
-312
-4,021
Accounts payable
2,000
-679
-1,510
500
Accrued expenses
3,585
-3,383
2,699
-2,308
Operating lease liability
-158
-38
-38
-37
Net cash used in operating activities
-14,738
-17,269
-13,254
-10,849
Purchase of property and equipment
176
82
0
7
Purchases of marketable securities
40,615
44,815
27,475
109,077
Proceeds from sale or maturities of marketable securities
35,814
83,326
24,097
13,928
Net cash provided by investing activities
-4,977
38,429
-3,378
-95,156
Proceeds from issuance of common stock and warrants
-
-
0
137,999
Issuance costs from issuance of common stock
-
-
0
8,638
Proceeds from exercise of common stock
0
3,854
1,275
-
Taxes paid related to net shares settlement of rsus
0
489
212
0
Net cash provided by (used in) financing activities
0
3,365
1,063
129,361
Net change in cash, cash equivalents and restricted cash
-19,715
24,525
-15,569
23,356
Cash, cash equivalents and restricted cash at beginning of period
55,736
31,211
46,780
44,051
Cash, cash equivalents and restricted cash at end of period
36,021
55,736
31,211
46,780
Cash and cash equivalents
35,453
-
-
-
Restricted cash
568
-
-
-
Total cash, cash equivalents and restricted cash
36,021
-
-
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net change in cash,cash equivalents and...-$19,715K (4.42%↑ Y/Y)Share-based compensation$4,822K (-9.10%↓ Y/Y)Accrued expenses$3,585K (-23.80%↓ Y/Y)Accounts payable$2,000K (478.03%↑ Y/Y)Rou assetamortization$355K (-27.70%↓ Y/Y)Depreciation andamortization$21K (-91.25%↓ Y/Y)Proceeds from sale ormaturities of marketable...$35,814K (-43.38%↓ Y/Y)Net cash used inoperating activities-$14,738K (41.14%↑ Y/Y)Net cash provided byinvesting activities-$4,977K (-195.20%↓ Y/Y)Canceled cashflow$10,783K Canceled cashflow$35,814K Net loss-$25,154K (31.11%↑ Y/Y)Purchases of marketablesecurities$40,615K (-29.98%↓ Y/Y)Amortization of premium anddiscount on marketable...-$198K (-94.12%↓ Y/Y)Operating lease liability-$158K (46.26%↑ Y/Y)Prepaid expenses andother current assets$11K (101.40%↑ Y/Y)Purchase of property andequipment$176K (877.78%↑ Y/Y)